CN1421241A - 一种治疗心脑血管疾病的复方丹参滴丸及其制备方法 - Google Patents
一种治疗心脑血管疾病的复方丹参滴丸及其制备方法 Download PDFInfo
- Publication number
- CN1421241A CN1421241A CN 02157381 CN02157381A CN1421241A CN 1421241 A CN1421241 A CN 1421241A CN 02157381 CN02157381 CN 02157381 CN 02157381 A CN02157381 A CN 02157381A CN 1421241 A CN1421241 A CN 1421241A
- Authority
- CN
- China
- Prior art keywords
- extract
- ethanol
- salviae miltiorrhizae
- radix notoginseng
- radix salviae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 240000007164 Salvia officinalis Species 0.000 title claims abstract description 99
- 235000005412 red sage Nutrition 0.000 title claims abstract description 66
- 239000006187 pill Substances 0.000 title claims abstract description 51
- 238000000034 method Methods 0.000 title claims description 25
- 150000001875 compounds Chemical class 0.000 title abstract description 43
- 230000000747 cardiac effect Effects 0.000 title description 4
- 230000002490 cerebral effect Effects 0.000 title 1
- 208000019553 vascular disease Diseases 0.000 title 1
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 137
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 137
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 113
- 239000000758 substrate Substances 0.000 claims abstract description 33
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000008118 PEG 6000 Substances 0.000 claims abstract description 11
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims abstract description 11
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims abstract description 7
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 536
- 239000000284 extract Substances 0.000 claims description 187
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 173
- 239000012141 concentrate Substances 0.000 claims description 85
- 239000000843 powder Substances 0.000 claims description 71
- 239000007788 liquid Substances 0.000 claims description 70
- 238000001035 drying Methods 0.000 claims description 67
- 239000000203 mixture Substances 0.000 claims description 56
- 238000005406 washing Methods 0.000 claims description 51
- 239000011347 resin Substances 0.000 claims description 50
- 229920005989 resin Polymers 0.000 claims description 50
- 238000010828 elution Methods 0.000 claims description 49
- 239000006210 lotion Substances 0.000 claims description 49
- 239000006228 supernatant Substances 0.000 claims description 48
- 244000131316 Panax pseudoginseng Species 0.000 claims description 42
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 42
- 239000003814 drug Substances 0.000 claims description 33
- 235000017276 Salvia Nutrition 0.000 claims description 32
- 239000008899 fufang danshen Substances 0.000 claims description 32
- 238000007670 refining Methods 0.000 claims description 30
- 238000000605 extraction Methods 0.000 claims description 26
- 239000012567 medical material Substances 0.000 claims description 23
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 23
- 239000000706 filtrate Substances 0.000 claims description 22
- 239000000469 ethanolic extract Substances 0.000 claims description 19
- 238000001556 precipitation Methods 0.000 claims description 18
- 238000010992 reflux Methods 0.000 claims description 18
- 229920002545 silicone oil Polymers 0.000 claims description 15
- 239000002826 coolant Substances 0.000 claims description 14
- 230000004927 fusion Effects 0.000 claims description 14
- 238000009413 insulation Methods 0.000 claims description 14
- 102000011759 adducin Human genes 0.000 claims description 11
- 108010076723 adducin Proteins 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 10
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 abstract description 47
- 230000000694 effects Effects 0.000 abstract description 12
- 238000002156 mixing Methods 0.000 abstract description 9
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- NCWQJOGVLLNWEO-UHFFFAOYSA-N methylsilicon Chemical compound [Si]C NCWQJOGVLLNWEO-UHFFFAOYSA-N 0.000 abstract 1
- 239000003921 oil Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 47
- 239000000243 solution Substances 0.000 description 46
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 32
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- 229940089161 ginsenoside Drugs 0.000 description 30
- 229930182494 ginsenoside Natural products 0.000 description 30
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 24
- 239000008187 granular material Substances 0.000 description 24
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 18
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 18
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 18
- 239000007921 spray Substances 0.000 description 17
- 239000002775 capsule Substances 0.000 description 16
- 229930183118 Tanshinone Natural products 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 229960003371 protocatechualdehyde Drugs 0.000 description 12
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 description 11
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 description 11
- 208000031225 myocardial ischemia Diseases 0.000 description 9
- 238000003908 quality control method Methods 0.000 description 9
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 8
- 229920000053 polysorbate 80 Polymers 0.000 description 8
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 239000000443 aerosol Substances 0.000 description 7
- 230000001476 alcoholic effect Effects 0.000 description 7
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 7
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 7
- 210000004907 gland Anatomy 0.000 description 7
- 229940039009 isoproterenol Drugs 0.000 description 7
- 239000007779 soft material Substances 0.000 description 7
- 102000004420 Creatine Kinase Human genes 0.000 description 6
- 108010042126 Creatine kinase Proteins 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000002354 daily effect Effects 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 229930189533 tanshinol Natural products 0.000 description 6
- 229920001353 Dextrin Polymers 0.000 description 5
- 239000004375 Dextrin Substances 0.000 description 5
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- 235000019425 dextrin Nutrition 0.000 description 5
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 5
- 239000007901 soft capsule Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 4
- 206010041956 Stasis syndrome Diseases 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 230000002785 anti-thrombosis Effects 0.000 description 4
- 208000005634 blind loop syndrome Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 229930004069 diterpene Natural products 0.000 description 4
- 125000000567 diterpene group Chemical group 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- -1 evaporate to dryness Substances 0.000 description 4
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 4
- YCOZIPAWZNQLMR-UHFFFAOYSA-N pentadecane Chemical compound CCCCCCCCCCCCCCC YCOZIPAWZNQLMR-UHFFFAOYSA-N 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 244000132619 red sage Species 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000010238 camphora Substances 0.000 description 3
- 229940025250 camphora Drugs 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- XYKZSUXWBGUGQV-UHFFFAOYSA-N 4,8-dimethylnaphtho[2,1-f][1]benzofuran-7,11-dione Chemical compound CC1=CC=CC2=C(C(C=3OC=C(C=3C3=O)C)=O)C3=CC=C21 XYKZSUXWBGUGQV-UHFFFAOYSA-N 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- UICCEPQXOQDRPC-UHFFFAOYSA-N [Na].C(CCCCCC)S(=O)(=O)O.CO Chemical compound [Na].C(CCCCCC)S(=O)(=O)O.CO UICCEPQXOQDRPC-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- IFXGUZKGCKIMQN-UHFFFAOYSA-N oxalonitrile;hydrate Chemical compound O.N#CC#N IFXGUZKGCKIMQN-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 1
- HARGZZNYNSYSGJ-UHFFFAOYSA-N 1,2 dihydrotanshinquinone Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)CO1 HARGZZNYNSYSGJ-UHFFFAOYSA-N 0.000 description 1
- YMGFTDKNIWPMGF-AGYDPFETSA-N 3-(3,4-dihydroxyphenyl)-2-[(e)-3-[2-[(e)-2-(3,4-dihydroxyphenyl)ethenyl]-3,4-dihydroxyphenyl]prop-2-enoyl]oxypropanoic acid Chemical compound C=1C=C(O)C(O)=C(\C=C\C=2C=C(O)C(O)=CC=2)C=1/C=C/C(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-AGYDPFETSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- HARGZZNYNSYSGJ-JTQLQIEISA-N Dihydrotanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2[C@@H](C)CO1 HARGZZNYNSYSGJ-JTQLQIEISA-N 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 1
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 description 1
- YMGFTDKNIWPMGF-UCPJVGPRSA-N Salvianolic acid A Chemical class C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-UCPJVGPRSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006502 antiplatelets effects Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- YTJJRAWFHJBAMT-UHFFFAOYSA-N depside Natural products OC(=O)CC1=C(O)C=C(O)C=C1OC(=O)C1=CC=C(O)C(O)=C1 YTJJRAWFHJBAMT-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 1
- XHALVRQBZGZHFE-UHFFFAOYSA-N rosmarinic acid methyl ester Natural products C=1C=C(O)C(O)=CC=1C=CC(=O)OC(C(=O)OC)CC1=CC=C(O)C(O)=C1 XHALVRQBZGZHFE-UHFFFAOYSA-N 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
组别 | 死亡时间(分) |
空白对照组模型对照组复方丹参制剂复方丹参制剂复方丹参制剂 | 31.8±8.63***16.0±3.6522.2±5.67**20.6±4.12*19.3±4.06 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02157381 CN1267111C (zh) | 2002-12-23 | 2002-12-23 | 一种治疗心脑血管疾病的复方丹参滴丸及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02157381 CN1267111C (zh) | 2002-12-23 | 2002-12-23 | 一种治疗心脑血管疾病的复方丹参滴丸及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1421241A true CN1421241A (zh) | 2003-06-04 |
CN1267111C CN1267111C (zh) | 2006-08-02 |
Family
ID=4752957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02157381 Expired - Lifetime CN1267111C (zh) | 2002-12-23 | 2002-12-23 | 一种治疗心脑血管疾病的复方丹参滴丸及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1267111C (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1778322B (zh) * | 2004-11-26 | 2010-04-28 | 天津天士力制药股份有限公司 | 一种治疗心血管疾病的药物 |
CN1778323B (zh) * | 2004-11-26 | 2010-05-12 | 天津天士力制药股份有限公司 | 一种治疗心血管疾病的药物滴丸 |
CN1919245B (zh) * | 2005-08-24 | 2011-07-13 | 天津天士力制药股份有限公司 | 一种治疗心血管疾病的中药组合物 |
CN102988476A (zh) * | 2012-08-23 | 2013-03-27 | 江苏苏南药业实业有限公司 | 一种复方丹参滴丸的制备方法 |
WO2015003661A1 (zh) * | 2013-07-11 | 2015-01-15 | 天士力制药集团股份有限公司 | 一种中药微滴丸的制备方法以及由所述方法制得的中药微滴丸 |
CN106478412A (zh) * | 2016-10-08 | 2017-03-08 | 贵州景峰注射剂有限公司 | 一种丹参素的提取方法 |
US10626077B2 (en) | 2013-08-29 | 2020-04-21 | Tasly Pharmaceutical Group Co., Ltd. | Salvianolic acid compound T, preparation method therefor, and use thereof |
USRE49035E1 (en) | 2013-07-11 | 2022-04-19 | Tasly Pharmaceutical Group Co., Ltd. | Traditional Chinese medicine composition, and preparation and application thereof |
USRE49050E1 (en) | 2013-07-11 | 2022-04-26 | Tasly Pharmaceutical Group Co., Ltd. | Traditional Chinese medicine composition, and preparation and application thereof |
-
2002
- 2002-12-23 CN CN 02157381 patent/CN1267111C/zh not_active Expired - Lifetime
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1778322B (zh) * | 2004-11-26 | 2010-04-28 | 天津天士力制药股份有限公司 | 一种治疗心血管疾病的药物 |
CN1778323B (zh) * | 2004-11-26 | 2010-05-12 | 天津天士力制药股份有限公司 | 一种治疗心血管疾病的药物滴丸 |
CN1919245B (zh) * | 2005-08-24 | 2011-07-13 | 天津天士力制药股份有限公司 | 一种治疗心血管疾病的中药组合物 |
CN102988476A (zh) * | 2012-08-23 | 2013-03-27 | 江苏苏南药业实业有限公司 | 一种复方丹参滴丸的制备方法 |
US11013694B2 (en) | 2013-07-11 | 2021-05-25 | Tasly Pharmaceutical Group Co., Ltd. | Formulation of a micro drop pill and the preparation method thereof |
KR20160028460A (ko) * | 2013-07-11 | 2016-03-11 | 타슬리 파마슈티컬 그룹 컴퍼니 리미티드 | 마이크로 점적 환제의 제형 및 이의 제조방법 |
EA034240B1 (ru) * | 2013-07-11 | 2020-01-21 | Тасли Фармасьютикал Груп Ко., Лтд. | Средство традиционной китайской медицины в форме капельной микропилюли и способ его получения |
WO2015003661A1 (zh) * | 2013-07-11 | 2015-01-15 | 天士力制药集团股份有限公司 | 一种中药微滴丸的制备方法以及由所述方法制得的中药微滴丸 |
KR102342819B1 (ko) | 2013-07-11 | 2021-12-22 | 타슬리 파마슈티컬 그룹 컴퍼니 리미티드 | 마이크로 점적 환제의 제형 및 이의 제조방법 |
USRE49035E1 (en) | 2013-07-11 | 2022-04-19 | Tasly Pharmaceutical Group Co., Ltd. | Traditional Chinese medicine composition, and preparation and application thereof |
USRE49050E1 (en) | 2013-07-11 | 2022-04-26 | Tasly Pharmaceutical Group Co., Ltd. | Traditional Chinese medicine composition, and preparation and application thereof |
US10626077B2 (en) | 2013-08-29 | 2020-04-21 | Tasly Pharmaceutical Group Co., Ltd. | Salvianolic acid compound T, preparation method therefor, and use thereof |
CN106478412A (zh) * | 2016-10-08 | 2017-03-08 | 贵州景峰注射剂有限公司 | 一种丹参素的提取方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1267111C (zh) | 2006-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101612362B (zh) | 一种调节血脂、防治心脑血管疾病复方制剂及其制备方法 | |
CN1419124A (zh) | 一种治疗心脑血管疾病的复方丹参制剂的质量控制方法 | |
CN1267111C (zh) | 一种治疗心脑血管疾病的复方丹参滴丸及其制备方法 | |
CN1296063C (zh) | 一种治疗心脑血管疾病的复方丹参制剂及其制备方法 | |
CN1762401A (zh) | 治疗心脑血管疾病的复方三七制剂及其制备方法和其应用 | |
CN1319519C (zh) | 一种治疗心脑血管疾病的复方丹参喷雾剂 | |
CN1309397C (zh) | 一种治疗心脑血管疾病的复方丹参胶囊及其制备方法 | |
CN1319521C (zh) | 一种治疗心脑血管疾病的复方丹参颗粒 | |
CN1876096A (zh) | 治疗妇女更年期综合症中药胶囊主药组分及其制备方法 | |
CN100488544C (zh) | 一种改进的治疗妇女更年期综合症的中药胶囊 | |
CN1422664A (zh) | 一种治疗心脑血管疾病的复方丹参制剂及其制备方法 | |
CN1853660A (zh) | 灯盏细辛制剂及其制备方法 | |
CN1320881C (zh) | 一种治疗急慢性肝炎的滴丸 | |
CN107913277A (zh) | 丹参酮抗尿酸性肾病的用途 | |
CN1582952A (zh) | 积雪草总苷在制备防治心、脑血管疾病药物中的用途 | |
CN100421683C (zh) | 一种治疗心脑血管疾病的复方丹参微囊制剂及其制备方法 | |
CN101732409B (zh) | 一种丹参软胶囊及其制备方法 | |
CN1899388A (zh) | 一种双丹软胶囊及其制备方法 | |
CN1762362A (zh) | 一种治疗心脑血管疾病的丹参成份药物组合物及其应用 | |
CN1899410A (zh) | 一种治疗心血管疾病的药物及其制备方法质量控制方法 | |
CN1695728A (zh) | 滋肾养肺的中药口服制剂及其制备方法 | |
CN1872250A (zh) | 一种治疗头痛的药物组合物 | |
CN1292738C (zh) | 用于补心益肾参茸滴丸及其制备方法 | |
CN1686240A (zh) | 冠心丹参微丸制剂及其制备方法 | |
CN1297256C (zh) | 一种用于治疗冠心病的口服滴丸制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: TIANJIN TASLY PHARMACY CO., LTD. Free format text: FORMER OWNER: BEIJING CAIRUI MEDICAL TECHNOLOGY CO., LTD. Effective date: 20100420 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: BEIJING CAIRUI MEDICAL TECHNOLOGY CO., LTD. Free format text: FORMER NAME: BEIJING CAIRUI MEDICINE CO., LTD. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100029 ROOM 601, WEITE OFFICE BUILDING, NO.A11,NORTH 3RD RING EAST ROAD, CHAOYANG DISTRICT, BEIJING CITY TO: 300410 TIANSHILI MODERM CHINESE MEDICINE CITY, NO.2, PUJIHE EAST ROAD, BEICHEN DISTRICT, TIANJIN CITY |
|
CP03 | Change of name, title or address |
Address after: 100029, Witt, office building 11, 601 North Third Ring Road, Beijing, Chaoyang District Patentee after: BEIJING CAIRUI MEDICAL TECHNOLOGY Co.,Ltd. Address before: 100029, Beijing, Chaoyang District cherry garden, 19 floor, 507 Patentee before: BEIJING CAIRUI MEDICINE Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100420 Address after: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee after: TIANJIN TASLY PHARMACEUTICAL Co.,Ltd. Address before: 100029, Witt, office building 11, 601 North Third Ring Road, Beijing, Chaoyang District Patentee before: BEIJING CAIRUI MEDICAL TECHNOLOGY Co.,Ltd. |
|
C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee before: TIANJIN TASLY PHARMACEUTICAL Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee before: TASLY PHARMACEUTICAL GROUP Co.,Ltd. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20060802 |